EXAI News and Press, Exscientia Limited From 05/03/22

Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T. A live webcast...

Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...

Exscientia's AI platform is used to identify promising molecules that can proceed to the next step of drug development by large pharmaceuticals like Sanofi. This technology partnership with Sanofi as well as Bristol-Myers brings millions of dollars of benefits to the cash flow. Th...

Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new resea...

Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia’s portfolio of investigational medicines. Exscientia ...

The following slide deck was published by Exscientia plc in conjunction with their 2021 Q4 earnings call. For further details see: Exscientia plc 2021 Q4 - Results - Earnings Call Presentation

Exscientia plc (EXAI) Q4 2021 Earnings Conference Call March 24, 2022 8:30 am ET Corporate Participants Sara Sherman - Vice President, Investor Relations Andrew Hopkins - Chief Executive Officer Ben Taylor - Chief Financial Officer and Chief Strategy Officer Dave Hallett - Chief Operations Of...

Exscientia press release (NASDAQ:EXAI): Q4 GAAP EPS of -£0.91. Revenue of £5.6M (+5.7% Y/Y). For further details see: Exscientia GAAP EPS of -£0.91, revenue of £5.6M

Company to host conference call and webcast on March 24, 2022 at 12:30 p.m. GMT / 8:30 a.m. ET Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close. Followin...

Program open at no-cost to any academic researcher interested in submitting a proposal Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a program designed to source cel...